Corrigendum to “Rutaecarpine prevented ox-LDL-induced VSMCs dysfunction through inhibiting overexpression of connexin 43”[Eur J Pharmacol.853(2019) 84–92/EJP-49538]

IF 4.2 3区医学 Q1 PHARMACOLOGY & PHARMACY

European journal of pharmacology Pub Date : 2025-05-14 DOI:10.1016/j.ejphar.2025.177694

Meiling Wang , Yusi Wu , Yanrong Yu , Yanqi Fu , Hang Yan , Xiaoying Wang , Tingting Li , Weijie Peng , Dan Luo

引用次数: 0

查看原文本刊更多论文

“Rutaecarpine通过抑制connexin 43的过度表达来预防ox- ldl诱导的VSMCs功能障碍”[J] .中国药理学杂志，2019,34(5):557 - 557。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of pharmacology 医学-药学

CiteScore

9.00

自引率

0.00%

发文量

572

审稿时长

34 days

期刊介绍： The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems. The scope includes: Behavioural pharmacology Neuropharmacology and analgesia Cardiovascular pharmacology Pulmonary, gastrointestinal and urogenital pharmacology Endocrine pharmacology Immunopharmacology and inflammation Molecular and cellular pharmacology Regenerative pharmacology Biologicals and biotherapeutics Translational pharmacology Nutriceutical pharmacology.